516 related articles for article (PubMed ID: 32217654)
1. The natural history of progressive fibrosing interstitial lung diseases.
Brown KK; Martinez FJ; Walsh SLF; Thannickal VJ; Prasse A; Schlenker-Herceg R; Goeldner RG; Clerisme-Beaty E; Tetzlaff K; Cottin V; Wells AU
Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32217654
[TBL] [Abstract][Full Text] [Related]
2. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
Brown KK; Inoue Y; Flaherty KR; Martinez FJ; Cottin V; Bonella F; Cerri S; Danoff SK; Jouneau S; Goeldner RG; Schmidt M; Stowasser S; Schlenker-Herceg R; Wells AU
Respirology; 2022 Apr; 27(4):294-300. PubMed ID: 35224814
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
4. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases.
Bonella F; Cottin V; Valenzuela C; Wijsenbeek M; Voss F; Rohr KB; Stowasser S; Maher TM
Adv Ther; 2022 Jul; 39(7):3392-3402. PubMed ID: 35576048
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial.
Inoue Y; Wells AU; Song JW; Xu Z; Kitamura H; Suda T; Okamoto M; Müller H; Coeck C; Rohr KB; Kolb M; Brown KK
Respirology; 2023 May; 28(5):465-474. PubMed ID: 36642509
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
[TBL] [Abstract][Full Text] [Related]
9. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib.
Richeldi L; Crestani B; Azuma A; Kolb M; Selman M; Stansen W; Quaresma M; Stowasser S; Cottin V
Respir Med; 2019 Sep; 156():20-25. PubMed ID: 31404749
[TBL] [Abstract][Full Text] [Related]
10. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Maher TM; Brown KK; Kreuter M; Devaraj A; Walsh SLF; Lancaster LH; Belloli EA; Padilla M; Behr J; Goeldner RG; Tetzlaff K; Schlenker-Herceg R; Flaherty KR;
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34210788
[TBL] [Abstract][Full Text] [Related]
11. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Cottin V; Martinez FJ; Jenkins RG; Belperio JA; Kitamura H; Molina-Molina M; Tschoepe I; Coeck C; Lievens D; Costabel U
Respir Res; 2022 Apr; 23(1):85. PubMed ID: 35392908
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
15. Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.
Matteson EL; Aringer M; Burmester GR; Mueller H; Moros L; Kolb M
Clin Rheumatol; 2023 Sep; 42(9):2311-2319. PubMed ID: 37209188
[TBL] [Abstract][Full Text] [Related]
16. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
17. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.
Wuyts WA; Kolb M; Stowasser S; Stansen W; Huggins JT; Raghu G
Lung; 2016 Oct; 194(5):739-43. PubMed ID: 27377558
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
[TBL] [Abstract][Full Text] [Related]
19. Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework.
Langford B; Diamantopoulos A; Maher TM; Inoue Y; Rohr KB; Baldwin M
Adv Ther; 2022 Feb; 39(2):1045-1054. PubMed ID: 34957531
[TBL] [Abstract][Full Text] [Related]
20. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
